GEP20074230B - Phosphate prodrugs of fluorooxindoles - Google Patents

Phosphate prodrugs of fluorooxindoles

Info

Publication number
GEP20074230B
GEP20074230B GEAP8458A GEAU2003008458A GEP20074230B GE P20074230 B GEP20074230 B GE P20074230B GE AP8458 A GEAP8458 A GE AP8458A GE AU2003008458 A GEAU2003008458 A GE AU2003008458A GE P20074230 B GEP20074230 B GE P20074230B
Authority
GE
Georgia
Prior art keywords
fluorooxindoles
phosphate prodrugs
enantiomer
racemate
disorders
Prior art date
Application number
GEAP8458A
Other languages
English (en)
Inventor
Kevin W Gillman
Piyasena Hewawasam
William D Schmitz
Omar D Lopez
John E Starrett
David P Provencal
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of GEP20074230B publication Critical patent/GEP20074230B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GEAP8458A 2002-03-20 2003-03-20 Phosphate prodrugs of fluorooxindoles GEP20074230B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36601002P 2002-03-20 2002-03-20

Publications (1)

Publication Number Publication Date
GEP20074230B true GEP20074230B (en) 2007-11-12

Family

ID=28454740

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP8458A GEP20074230B (en) 2002-03-20 2003-03-20 Phosphate prodrugs of fluorooxindoles

Country Status (21)

Country Link
US (1) US6930100B2 (enExample)
EP (1) EP1485085A4 (enExample)
JP (1) JP4359150B2 (enExample)
KR (1) KR100951499B1 (enExample)
CN (1) CN100384820C (enExample)
BR (1) BR0308737A (enExample)
CA (1) CA2479256A1 (enExample)
CO (1) CO5611143A2 (enExample)
GE (1) GEP20074230B (enExample)
HR (1) HRP20040853A2 (enExample)
IL (2) IL164022A0 (enExample)
IS (1) IS7456A (enExample)
MX (1) MXPA04008999A (enExample)
NO (1) NO20044442L (enExample)
NZ (1) NZ535365A (enExample)
PL (1) PL372413A1 (enExample)
RS (1) RS81904A (enExample)
RU (1) RU2312857C2 (enExample)
UA (1) UA77296C2 (enExample)
WO (1) WO2003080047A1 (enExample)
ZA (1) ZA200407337B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
US6916937B2 (en) * 2003-02-03 2005-07-12 Bristol-Myers Squibb Company Carbohydrate prodrugs of fluorooxindoles
US8178671B2 (en) 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
US7169803B2 (en) * 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
EP1856135B1 (en) 2005-01-19 2009-12-09 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8227455B2 (en) * 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
WO2007032263A1 (ja) * 2005-09-13 2007-03-22 Eisai R & D Management Co., Ltd. 安定性が改善されたクロロメチルフォスフェイト誘導体を含む組成物およびその製造方法
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
WO2009100090A1 (en) * 2008-02-05 2009-08-13 Merck & Co., Inc. Prodrugs of cgrp receptor antagonist
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
HRP20171415T4 (hr) 2009-06-25 2023-03-03 Alkermes Pharma Ireland Limited Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja
WO2010151711A1 (en) * 2009-06-25 2010-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds
WO2011163594A2 (en) * 2010-06-24 2011-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
SG11201702041PA (en) 2015-07-06 2017-04-27 Gilead Sciences Inc Cot modulators and methods of use thereof
PE20211305A1 (es) 2018-01-05 2021-07-20 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas
CN112218867B (zh) * 2018-03-05 2023-11-21 泰昂治疗公司 腺苷受体拮抗剂及其用途
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CR20220058A (es) 2019-07-10 2022-07-19 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos
CR20220057A (es) 2019-07-10 2022-07-19 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
CN115397511A (zh) 2020-03-30 2022-11-25 吉利德科学公司 Cot抑制剂化合物(s)-6-(((1-(双环[1.1.1]戊-1-基)-1h-1,2,3-三唑-4-基)2-甲基-1-氧代-1,2-二氢异喹啉-5-基)甲基)))氨基8-氯-(新戊基氨基)喹啉-3-甲腈的固体形式
US11845737B2 (en) 2020-04-02 2023-12-19 Gilead Sciences, Inc. Process for preparing a Cot inhibitor compound
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
WO2025233532A1 (en) 2024-05-10 2025-11-13 Les Laboratoires Servier Maxi-k potassium channel openers and therapeutic applications thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU749063A1 (ru) * 1979-01-29 1996-09-10 Военно-медицинская академия им.С.М.Кирова 3-(4-карбэтокси)-фенилимино-2-оксоиндолин, повышающий устойчивость организма к повторной черепно-мозговой травме
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5187173A (en) * 1991-12-27 1993-02-16 Sterling Winthrop Inc. 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
CA2317008C (en) 1997-12-31 2009-01-20 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
CA2318817A1 (en) * 1998-01-29 1999-08-05 Bristol-Myers Squibb Company Phosphate derivatives of diaryl 1,3,4-oxadiazolone

Also Published As

Publication number Publication date
PL372413A1 (en) 2005-07-25
US20030195169A1 (en) 2003-10-16
EP1485085A4 (en) 2007-03-14
KR20040106293A (ko) 2004-12-17
IS7456A (is) 2004-09-17
NZ535365A (en) 2006-07-28
CN1652769A (zh) 2005-08-10
EP1485085A1 (en) 2004-12-15
BR0308737A (pt) 2005-01-11
RS81904A (sr) 2007-02-05
WO2003080047A1 (en) 2003-10-02
JP2005526097A (ja) 2005-09-02
CN100384820C (zh) 2008-04-30
JP4359150B2 (ja) 2009-11-04
IL164022A0 (en) 2005-12-18
RU2004131201A (ru) 2005-05-10
CA2479256A1 (en) 2003-10-02
RU2312857C2 (ru) 2007-12-20
UA77296C2 (en) 2006-11-15
HRP20040853A2 (en) 2004-12-31
CO5611143A2 (es) 2006-02-28
MXPA04008999A (es) 2004-12-07
US6930100B2 (en) 2005-08-16
IL164022A (en) 2008-04-13
ZA200407337B (en) 2006-02-22
AU2003215017A1 (en) 2003-10-08
KR100951499B1 (ko) 2010-04-07
NO20044442L (no) 2004-10-19

Similar Documents

Publication Publication Date Title
GEP20074230B (en) Phosphate prodrugs of fluorooxindoles
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
NO20060847L (no) Substituert 2-aminotetralin til behandling av depresjon
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
BR0313070A (pt) Métodos para preparação de um diastereÈmero desejado de uma tetraidro-beta-carbolina e para preparação de um composto
GEP20084435B (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
MXPA05013752A (es) Procedimiento e intermediarios para la preparacion de (1r,2s,5s)-6,6-dimetil-3-azabiciclo[3,1,0]exan-2-carboxilatos o sales de los mismos.
GEP20074055B (en) Nicotinamide derivatives useful as pde4 inhibitors
GEP20105082B (en) (biphenyl) carboxylic acids and derivatives thereof
HRP20041202A2 (en) Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof
TNSN04250A1 (en) Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof.
MY140164A (en) Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same
WO2004041802A8 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.
WO2003101996A8 (en) Esters in position 20 of camptothecins
MXPA05007484A (es) Derivados de diarilmetilidina piperidina, preparacion y uso de los mismos.
SE0203300D0 (sv) Novel Compounds
AU2003271811A8 (en) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
WO2006058720A3 (en) Novel compounds for the treatment of neurological disorders
WO2004022542A3 (de) Substituierte 1,2,3,4-tetrahydrochinolinderivate
WO2003075824A3 (en) Process of manufacturing pharmaceutical composition useful for management of tuberculosis
UA81664C2 (ru) Производные дифенилмочевины и их применение, как блокаторов хлоридных каналов
MY136138A (en) Hexacyclic compounds
MXPA05007483A (es) Derivados de diarilmetilidina piperidina, preparacion y uso de los mismos.
GEP20084296B (en) Novel 3-(4-oxo-4h-chromen-2-yl)-(1h)-quinoline-4-one derivatives, method for preparing same and pharmaceutical compositions containing same